TFF Pharmaceuticals, Inc. (TFFP) is a leading clinical-stage biopharmaceutical company primarily focused on the development and commercialization of its novel leading drug candidates which are dependent on thin film freezing (TFF) technology. The company basically has two lead drug candidates including inhaled voriconazole powder (TFF VORI is in phase 1 trials for prevention of invasive pulmonary aspergillosis) and another one is inhaled tacrolimus powder (phase 1 trials for prevention of lung transplant rejection). The company has 42 patents registered to its name.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
The price of TFFP stock in the regular trading of December 21, 2021, with a slight rise of 0.83% was $8.54. At last check in the aftermarket, the stock further notably inclined by 5.39%.
Events and Happenings
On December 21, 2021, TFFP reported its complete readout of safety and pharmacokinetics information from Phase 1 clinical trials of TFF VORI in asthma patients. On December 06, 2021, TFFP reported that it hosted a science day in relation to two of the TFFP’s lead candidates, TFF VORI for invasive pulmonary aspergillosis (IPA) and inhaled AUG-3387 for COVID-19, on December 13, 2021.
On November 15, 2021, TFFP announced its financial results for the third quarter ended September 30, 2021. Some of the key updates are as follows
Net Loss per Share
The company reported basic and diluted net loss per share for the third quarter of 2021 to be $8.7 million or $0.34 per share, as opposed to the same period of 2020 when it was $5.1 million or $0.24 per share.
The grant revenue as reported by the company for Q3 2021 was $0.05 million.
Total Current Assets
Total current assets of the company for Q3 2021 were $47.4 million.
On November 08, 2021, TFFP reported that the top management of the company represented at the 12th Annual Jefferies London Healthcare Conference held on November 16-19, 2021. On October 28, 2021, TFFP reported about the receipt of approval from Health Canada to start clinical trials Phase 1 for a dry powder medication of niclosamide, which is an antiviral drug with possible potential to cure COVID-19.
On October 14, 2021, TFFP and Augmenta Bioworks reported about their collaboration for a monoclonal antibody (mAb) therapy. Both companies announced the publication of a research paper showing optimistic outcomes of AUG-3387 for the treatment of SARS-CoV-2 infection. On September 23, 2021, TFFP reported topline Phase 1 clinical trial results from the study showing Tacrolimus Inhalation Powder as a safe and low dose drug level therapeutic potential.
The stock of TFFP showed a tremendous surge of 18% from the past month which clearly shows the potential of the company to attract investors. The company has already developed sound strategies regarding its business plans. The after-market incline is possibly the result of the positive data from the drug safety testing for asthma patients.